Suicide after successful deep brain stimulation for movement disorders.
Albanese
A
A
Piacentini
S
S
Romito
L M A
LM
Leone
M
M
Franzini
A
A
Broggi
G
G
Bussone
G
G
D000328:Adult; D000978:Antiparkinson Agents / Q000009:adverse effects; D015984:Causality; D002986:Clinical Trials as Topic / Q000592:standards; D015897:Comorbidity; D046690:Deep Brain Stimulation / Q000009:adverse effects* / Q000523:psychology*; D003704:Dementia / Q000453:epidemiology / Q000523:psychology; D003866:Depressive Disorder / Q000453:epidemiology / Q000523:psychology*; D005260:Female; D006801:Humans; D007034:Hypothalamus, Posterior / Q000503:physiopathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000523:psychology* / Q000628:therapy*; D020734:Parkinsonian Disorders / Q000523:psychology / Q000628:therapy; D018579:Patient Selection; D012189:Retrospective Studies; D012307:Risk Factors; D020531:Subthalamic Nucleus / Q000503:physiopathology / Q000601:surgery; D013405:Suicide / Q000523:psychology* / Q000706:statistics & numerical data; D013557:Switzerland / Q000453:epidemiology; D000092864:Suicide Prevention
D000978:Antiparkinson Agents